Thymic Engraftment in SCID-hu Mice by CD4− CD34++ Lin− LDFL and CD4+ CD34++ Lin− LDFL Progenitors
| Donor . | Progenitor Population . | No. Injected . | Day of Analysis . | Fraction Engrafted* . | % DP† . | % CD4+ SP† . | % CD8+ SP† . |
|---|---|---|---|---|---|---|---|
| A | CD4− | 2.0 × 103 | 54 | 3/4 | 68.6-79.3 | 9.6-14.1 | 10.6-17.4 |
| A | CD4+ | 2.0 × 103 | 54 | 1/1 | 59.9 | 19.3 | 20.9 |
| B | CD4− | 2.0 × 102 | 68 | 1/2 | 8.0 | 18.9 | 46.3 |
| B | CD4+ | 2.0 × 102 | 68 | 3/3 | 58.7-90.1 | 4.5-16.0 | 3.6-20.0 |
| C | CD4− | 50 | 82 | 2/2 | 8.6-52.8 | 2.2-5.3 | 3.9-11.2 |
| C | CD4+ | 50 | 82 | 1/1 | 56.4 | 4.1 | 2.6 |
| D | CD4+ | 5.0 × 103 | 83 | 2/6 | 8.2-19.9 | 40.2-45.0 | 39.7-44.9 |
| D | CD4+ | 5.0 × 103 | 95 | 2/3 | 62.9-83.4 | 7.3-15.5 | 8.4-18.7 |
| D | CD4+ | 5.0 × 102 | 95 | 0/2 | 0 | 0 | 0 |
| D | CD4+ | 50 | 95 | 1/2 | 80.3 | 9.1 | 10.1 |
| Donor . | Progenitor Population . | No. Injected . | Day of Analysis . | Fraction Engrafted* . | % DP† . | % CD4+ SP† . | % CD8+ SP† . |
|---|---|---|---|---|---|---|---|
| A | CD4− | 2.0 × 103 | 54 | 3/4 | 68.6-79.3 | 9.6-14.1 | 10.6-17.4 |
| A | CD4+ | 2.0 × 103 | 54 | 1/1 | 59.9 | 19.3 | 20.9 |
| B | CD4− | 2.0 × 102 | 68 | 1/2 | 8.0 | 18.9 | 46.3 |
| B | CD4+ | 2.0 × 102 | 68 | 3/3 | 58.7-90.1 | 4.5-16.0 | 3.6-20.0 |
| C | CD4− | 50 | 82 | 2/2 | 8.6-52.8 | 2.2-5.3 | 3.9-11.2 |
| C | CD4+ | 50 | 82 | 1/1 | 56.4 | 4.1 | 2.6 |
| D | CD4+ | 5.0 × 103 | 83 | 2/6 | 8.2-19.9 | 40.2-45.0 | 39.7-44.9 |
| D | CD4+ | 5.0 × 103 | 95 | 2/3 | 62.9-83.4 | 7.3-15.5 | 8.4-18.7 |
| D | CD4+ | 5.0 × 102 | 95 | 0/2 | 0 | 0 | 0 |
| D | CD4+ | 50 | 95 | 1/2 | 80.3 | 9.1 | 10.1 |
Engraftment of human fetal thymic tissue implanted in SCID mice by HLA-mismatched fetal liver progenitors was defined as the presence of donor-derived CD3+, CD4 SP, CD8 SP, and CD4 CD8 DP T cells as determined by FACScan analysis.
The data are presented as the range in the percentage of each subpopulation observed among total thymocytes expressing the donor HLA phenotype.